Benitec Biopharma (BNTC) Stock Price, News & Analysis

Company Overview

Founded in 1997 and headquartered in Melbourne, Australia, Benitec Biopharma plc is a clinical-stage biotechnology company focused on the development of gene-silencing therapies. The company specializes in DNA-directed RNA interference (ddRNAi), a platform designed to silence disease-causing genes at the mRNA level. Benitec’s approach employs engineered DNA constructs that instruct cells to produce short interfering RNAs (siRNAs), offering a potentially durable and precise treatment modality.

Benitec has established strategic collaborations with leading academic institutions and biopharmaceutical organizations to advance its ddRNAi programs. The technology is adaptable across multiple delivery platforms, notably adeno-associated virus (AAV) vectors, which facilitate targeted delivery of genetic constructs. This flexibility underpins the company’s efforts to address a range of therapeutic areas with high unmet medical need.

The company’s pipeline includes a lead candidate in chronic hepatitis B aimed at achieving sustained viral suppression through targeted gene silencing. In parallel, Benitec is exploring ddRNAi-based approaches for HTLV-1-associated diseases and fibrotic disorders such as idiopathic pulmonary fibrosis, with the goal of modulating pathological gene expression drivers. Earlier-stage research has also investigated applications in neurodegenerative conditions, reflecting the broad applicability of RNA interference strategies in both hepatology and neurology.

Benitec serves global markets with operations in Australia and the United States, supported by a network of collaborators in Europe and Asia. The company is governed by a board of directors and an experienced management team with deep expertise in gene therapy development, regulatory strategy and commercialization. Through its ddRNAi platform, Benitec Biopharma continues to advance novel therapeutic candidates toward clinical evaluation, addressing diseases with significant unmet patient needs.

Key Stats

• Today's Range: $12.70 to $12.98
• 50-Day Range: $11.35 to $16.56
• 52-Week Range: $7.05 to $17.15
• Volume: 4,664 shs
• Average Volume: 56,224 shs
• Market Capitalization: $334.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.83
• Consensus Rating: Buy

Benitec Biopharma Stock Analysis - MarketRank™

Benitec Biopharma scored higher than 43% of companies evaluated by MarketBeat, and ranked 621st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Benitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Benitec Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Benitec Biopharma are expected to decrease in the coming year, from ($1.48) to ($2.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Benitec Biopharma is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Benitec Biopharma is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Benitec Biopharma has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.04% of the float of Benitec Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Benitec Biopharma has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Benitec Biopharma has recently increased by 18.40%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Benitec Biopharma does not currently pay a dividend.

Dividend Growth

Benitec Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.04% of the float of Benitec Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Benitec Biopharma has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Benitec Biopharma has recently increased by 18.40%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.54

News Sentiment

Benitec Biopharma has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Benitec Biopharma this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for BNTC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Benitec Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Benitec Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.30% of the stock of Benitec Biopharma is held by insiders.

Percentage Held by Institutions

52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BNTC Stock Analysis - Frequently Asked Questions

How have BNTC shares performed this year?

Benitec Biopharma's stock was trading at $12.63 at the beginning of 2025. Since then, BNTC shares have increased by 4.7% and is now trading at $13.22.

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Limited (NASDAQ:BNTC) posted its earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.12.

When did Benitec Biopharma's stock split?

Benitec Biopharma's stock reverse split on the morning of Wednesday, July 26th 2023.The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Benitec Biopharma IPO?

Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), ADMA Biologics (ADMA), AVEO Pharmaceuticals (AVEO), BioLineRx (BLRX), Exelixis (EXEL) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 9/25/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNTC
• CIK: 1808898
• Web: www.benitec.com
• Phone: 510-780-0819
• Fax: 61 (0)3 9966-9923
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Benitec Biopharma: $23.83
• High Price Target: $35.00
• Low Price Target: $13.00
• Potential Upside/Downside: +88.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.26%
• Return on Assets: -35.71%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 14.80
• Quick Ratio: 14.80

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 4,140.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.68 per share
• Price / Book: 2.70

Miscellaneous

• Outstanding Shares: 26,250,000
• Free Float: 25,909,000
• Market Cap: $331.28 million
• Optionable: No Data
• Beta: 0.37